Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
80
TVTX Quote, Financials, Valuation and Earnings
Last price:
$40.3200
Seasonality move
:
33.23%
Day range:
$36.0100 - $42.1300
52-week range:
$12.9100 - $37.5000
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.36x
P/B ratio:
43.01x
Volume:
933K
Avg. volume:
1.6M
1-year change:
135.14%
Market cap:
$3.2B
Revenue:
$233.2M
EPS (TTM):
-$1.08
Analysts' Opinion
-
Consensus RatingTravere Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $41.6429, Travere Therapeutics, Inc. has an estimated upside of 17.77% from its current price of $40.2800.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $31.0000 representing 12.33% downside risk from its current price of $40.2800.
Fair Value
-
According to the consensus of 14 analysts, Travere Therapeutics, Inc. has 17.77% upside to fair value with a price target of $41.6429 per share.
TVTX vs. S&P 500
-
Over the past 5 trading days, Travere Therapeutics, Inc. has underperformed the S&P 500 by -3.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Travere Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Travere Therapeutics, Inc. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Travere Therapeutics, Inc. reported revenues of $164.9M.
Earnings Growth
-
Travere Therapeutics, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Travere Therapeutics, Inc. reported earnings per share of $0.25.
Enterprise value:
3.2B
EV / Invested capital:
8.03x
Price / LTM sales:
7.36x
EV / EBIT:
--
EV / Revenue:
7.43x
PEG ratio (5yr expected):
-1.38x
EV / Free cash flow:
-30.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$370.8M
Return On Assets:
-16.15%
Net Income Margin (TTM):
-20.32%
Return On Equity:
-263.9%
Return On Invested Capital:
-21.07%
Operating Margin:
15.12%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $157M | $203.4M | $435.8M | $62.9M | $164.9M | |
| Gross Profit | $107.4M | $150.4M | $370.8M | $50M | $147.5M | |
| Operating Income | -$354.8M | -$279.7M | -$89.7M | -$56M | $24.9M | |
| EBITDA | -$313.5M | -$236.4M | -$35M | -$44.8M | $40.7M | |
| Diluted EPS | -$4.40 | -$4.56 | -$1.08 | -$0.70 | $0.25 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $579.1M | $534.8M | $686.2M | $324.7M | $371.1M | |
| Total Assets | $775.1M | $726.2M | $832.9M | $504.4M | $538.6M | |
| Current Liabilities | $113.2M | $131M | $139.4M | $190M | $135.1M | |
| Total Liabilities | $467.7M | $625.5M | $553.1M | $534.9M | $465M | |
| Total Equity | $307.4M | $100.7M | $279.8M | -$30.5M | $73.6M | |
| Total Debt | $256.2M | $403.4M | $400.7M | $397.1M | $324M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$264.2M | -$272.2M | -$58.6M | -$42.5M | $14.3M | |
| Cash From Investing | $36M | $162.7M | $52.4M | $46.1M | $86.6M | |
| Cash From Financing | $219.2M | $427K | $79M | $46K | -$65.3M | |
| Free Cash Flow | -$305.1M | -$304.4M | -$107.5M | -$50.7M | -$871K | |
TVTX
Sector
Market Cap
$3.2B
$28.1M
Price % of 52-Week High
94.29%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-6.33%
-1.49%
1-Year Price Total Return
106.18%
-17.13%
Beta (5-Year)
0.886
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$35.6994
200-day SMA
Buy
Level
$22.1970
Bollinger Bands (100)
Buy
Level
20.7309 - 34.2909
Chaikin Money Flow
Sell
Level
-2.3M
20-day SMA
Buy
Level
$35.2323
Relative Strength Index (RSI14)
Buy
Level
69.3466
ADX Line
Buy
Level
25.6407
Williams %R
Neutral
Level
-45.1613
50-day SMA
Buy
Level
$33.4307
MACD (12, 26)
Buy
Level
9.6749
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Neutral
Level
7.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.2961)
Sell
CA Score
(Annual)
Level (-3.4362)
Buy
Beneish M-Score
(Annual)
Level (-2.7109)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.9433)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, TVTX has received 12 Buy ratings 2 Hold ratings, and 0 Sell ratings. The TVTX average analyst price target in the past 3 months is $41.6429.
-
Where Will Travere Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Travere Therapeutics, Inc. share price will rise to $41.6429 per share over the next 12 months.
-
What Do Analysts Say About Travere Therapeutics, Inc.?
Analysts are divided on their view about Travere Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Travere Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $31.0000.
-
What Is Travere Therapeutics, Inc.'s Price Target?
The price target for Travere Therapeutics, Inc. over the next 1-year time period is forecast to be $41.6429 according to 14 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is TVTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Travere Therapeutics, Inc. is a Buy. 12 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TVTX?
You can purchase shares of Travere Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Travere Therapeutics, Inc. shares.
-
What Is The Travere Therapeutics, Inc. Share Price Today?
Travere Therapeutics, Inc. was last trading at $40.3200 per share. This represents the most recent stock quote for Travere Therapeutics, Inc.. Yesterday, Travere Therapeutics, Inc. closed at $40.2800 per share.
-
How To Buy Travere Therapeutics, Inc. Stock Online?
In order to purchase Travere Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TVTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TVTX
Sector
P/E ratio
--
23.89x
PEG ratio
-1.38x
-0.01x
P/B ratio
43.01x
1.81x
Price / LTM sales
7.36x
1.59x
Growth Metrics
TVTX
Sector
Revenue growth
162.11%
4.62%
Earnings growth
135.55%
11.06%
Revenue (5-year growth)
5.87%
6.5%
Earnings forecast
-$0.09
-$0.21
Profitability
TVTX
Sector
Profitability FY 2024
$181.9M
$3.6M
Return on invested capital
-21.07%
-31.84%
Return on assets
-16.15%
-27.96%
Return on equity
-263.9%
-37.63%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Feb
19
Estimated Next Earnings Date
Jan
29
Balance Sheet
TVTX
Sector
Total cash
$254.5M
$26.4M
Short term investments
$312.2M
$25.7M
Total assets
$594.1M
$76.9M
Long term debt
$324M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
